Remedium Lifecare Q4 Results Analysis

Remedium Lifecare, a pharmaceutical company, recently announced their Q4 results for the year 2024. The results revealed a significant increase in the topline by 1763.59%, but also a substantial increase in losses by 1023.55% year-over-year. Compared to the previous quarter, the revenue declined by 23.21% while the losses increased by 217.25%.

One of the key highlights of the financial report was the rise in Selling, general & administrative expenses by 7.39% quarter-over-quarter, but a decrease by 36.16% year-over-year. The operating income also saw a significant decline of 146.73% quarter-over-quarter and a decrease of 1004.48% year-over-year.

The earnings per share (EPS) for Q4 was reported at ₹-149.22, marking a drastic decrease of 25988.78% year-over-year. Additionally, Remedium Lifecare has delivered negative returns of -8.49% in the last week, -21.59% in the last 6 months, and -26.9% year-to-date.

As of now, Remedium Lifecare has a market capitalization of ₹738.86 Cr with a 52-week high/low of ₹179.66 and ₹66.85 respectively.

The company’s financials for Q4 compared to the previous quarter and year-over-year show fluctuations in total revenue, operating expenses, and net income. The Q4 profit/loss was reported at ₹-53.72Cr, and the Q4 revenue stood at ₹1408.49Cr.

Investors and stakeholders are advised to stay updated on quarterly results with the company’s results calendar to make informed decisions. For more business coverage and market insights, visit Mint, India’s #1 news destination.

For further information on topics of interest, explore the related sections provided by Mint.